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INTRODUCTION
Inflammatory bowel disease (IBD) is a group 
of  chronic conditions affecting the digestive tract 
in different locations(11). The mechanisms under-
lying the disease are not yet fully understood and 
its incidence has been increasing since the end of 
the past century, with important consequences for 
public health(26).
Crohn’s disease (CD) and ulcerative colitis (UC) 
are the most common presentations of  IBD(12). Both 
are characterized by chronic inflammation at intesti-
nal and systemic level that seems to arise in response 
to an abnormal immunological reaction to the 
intestinal microbiota or other stimuli in susceptible 
individuals(3, 22). Throughout its course IBD is also 
characterized by periods of  activity and remission 
and features a wide variety of  manifestations at 
intestinal and extra-intestinal sites(1, 8, 12). According 
to some authors, 25%-30% of the patients diagnosed 
with IBD have at least one extra-intestinal manifes-
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tation, being the oral cavity one of  the most affected 
areas(1, 8, 21). The oral lesions include affections in the 
mucosa, periodontal tissues and tooth tissue, and 
have been said to play a role as an early indicator of 
IBD or at least as concomitant manifestations that 
could help with the diagnose(6, 10, 12, 19, 24).
In general, oral mucosal lesions described in the 
literature may arise either in patients with CD or UC 
and may be specific or nonspecific for these patholo-
gies(6, 8, 24). Some authors cite diffuse swellings of the 
oral and perioral tissues as the most prominent fea-
tures(18) but there have been reports of a great variety 
of pathological features in this patients(2, 15). Further-
more, it has been observed a higher prevalence of 
other oral symptoms as halitosis, nausea, xerostomia 
and regurgitation in patients with IBD(15).
The aim of  this study was to evaluate the asso-
ciation between IBD and oral mucosal lesions and 
symptoms, and complementary to evaluate their 
possible relation with oral hygiene, smoking habits, 
drug therapy, duration and activity of IBD.
DOI: 10.1590/S0004-28032015000200006
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METHODS
The study was conducted at General Gastroenterology 
and Inflammatory Disease Clinic of the Hospital Garcia de 
Orta (HGO), in Almada, Portugal. The protocol used for 
data collection was previously reviewed and approved by the 
Ethics Commission of HGO.
Patients who had been previously diagnosed with ulcer-
ative colitis or Crohn’s disease and who agreed to participate 
in this study were selected, having healthy individuals which 
were accompanying the study group patients to their appoint-
ments as the control group. Informed consent was obtained 
from all participants and the study design was in accordance 
with the Declaration of Helsinki.
Exclusion criteria were: patients under 18 years old, 
pregnant women, edentulous patients, patients with fixed 
orthodontic appliances, patients in need of prophylaxis for 
bacterial endocarditis, patients without a clear diagnosis of 
ulcerative colitis or Crohn’s disease and patients with other 
diseases that could interfere with the variables in study.
The assessment of  disease activity was previously per-
formed by the HGO gastroenterology team according to 
the Harvey-Bradshaw Index(14) for CD and according to the 
Montreal Index of  Activity(23) for UC. The diseases were 
considered inactive for scores of 5 or less in the Harvey-Brad-
shaw Index (CD) and for S0 ratings in the Montreal Index 
of Activity (UC).
The patients were divided in five groups referring to the 
drug therapy: untreated; under salicylate therapy; under 
corticosteroids therapy; treated with immunosuppressant 
drugs - azathioprine and cyclosporine - and under biological 
therapy - infliximab and adalimumab. Patients treated with 
more than one drug were included in the group that most 
influences the evolution of the disease. In increasing order: 
salicylates, corticosteroids, immunosuppressant drugs, bio-
logical therapy.
Two groups were considered for the assessment of 
smoking habits: smokers and non-smokers. All individuals 
who reported smoking habits regardless of frequency were 
considered in the smokers group. Ex-smokers were classified 
as non-smokers.
Disease duration was divided into three ranges: short 
term [up to 3 years]; average term [more than 3 to 9 years] 
and long term [longer than 9 years].
Clinical data
Patients admitted in the study answered a standardized 
questionnaire, in order to record the following information: 
age, gender, medical history, medication, smoking habits and 
oral hygiene habits.
Patients were also asked to indicate all the oral symp-
toms they have experienced recently from a list containing: 
xerostomia, halitosis, dysphagia, regurgitation, dysgeusia 
and acid taste.
Oral examination
Data was collected by a team directed by the main inves-
tigator. Clinical observation was always performed by the 
same examiner, while another research team element pointed 
out data simultaneously, eliminating protocol differences and 
preserving the results agreement.
The search for oral lesions in the mucosa and surrounding 
soft tissues, started at the lips vermillion, then labial mucosa, 
followed by the buccal mucosa, gums, palate and tongue in 
this specific order. All the oral lesions detected were then 
registered.
Statistical analysis
The data collected from the questionnaires and intraoral 
examination was inserted in Microsoft Excel™ and SPSS™ 
(Statistical Package for Social Sciences) for analysis and 
statistical processing. 
To describe and summarize the data obtained in the 
sample, descriptive statistics measures were performed. 
Kolmogorov-Smirnov tests were used to test the normality 
of the sample; Spearman correlation tests, Fisher exact test 
and Kruskal-Wallis tests were then used to verify the cor-
relation strength between these variables with a confidence 
level of 95%.
RESULTS
Sample characterization
Initially, 183 individuals were observed, from which 12 did 
not meet the established criteria. As a result, a final number 
of 171 individuals were included in the study - 113 (66.1%) 
patients in the study group and 58 (33.9%) individuals in 
the control group.
The average age of the sample was 45.5±16.9 years, the 
minimum age was 19 years old and maximum 81 year old. 
Eighty-five (49.7%) individuals were male and 86 (50.3%) 
were female. In the total sample there was 85.4% (n=146) of 
non-smoker subjects, and 14.6% (n=25) of smoker patients.
The IBD study group consisted of 57 (50.4%) males and 
56 (49.6%) females, with a mean age of  44.5±17.2 years, 
with a minimum of 19 and maximum of 81 years old. 83.2% 
(n=94) of this group were non-smoker patients, against 16.8% 
(n=19) smokers.
A total of 15% (n=17) of the 113 patients were under-
going active disease, and 85% (n=96) were in remission. 
The most common diagnosis was Crohn’s disease in 57.5% 
(n=65), the remaining patients (n=48) were diagnosed with 
ulcerative colitis (Table 1).
The control group was composed of 28 (48.3%) male and 
30 (51.7%) female individuals. The mean age was 47.4±16.3 
years, with a minimum of 19 and maximum of 77 years old. 
Fifty-two (89.7%) were non-smoking, against 6 (10.3%) 
smokers (Table 1).
All individuals reported brushing their teeth at least once 
a day (on average 2 brushings in the study group and 1.8 in 
the control group). The use of dental floss has been reported 
in 20.4% (n=23) of the study group and 8.6% (n=5) of the 
control group. The mouthwashes were not regularly used by 
the majority of the patients (Figure 1).
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FIGURE 2. Distribution of lesions of the oral mucosa in the study and 
control groups.
TABLE 1. Demographic data of the groups (CD, UC and Control) for 
our sample
  CD (n=65) P1
UC 
(n=48) P2
Controls 
(n= 58)
Age 41.1 (15.2) 0.030
49.2 
(18.4) 0.599
47.4 
(16.3)
Masculine 32 0.916 25 0.696 28
Feminine 33 0.916 23 0.696 30
Caucasian 63 0.340 47 0.376 57
Black 2 <0.001 0 n.d. 1
Smoker 13 <0.001 6 <0.001 6
Non-smoker 52 0.004 42 0.001 52
Active disease 9 - 8 - -
(χ) Standard deviation of respective datasets. (P1): significance of the differences between CD 
and Control; (P2): significance of the differences between control and UC.
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Clinical data
Case-control comparison
In the study group we detected the presence of aphthous 
ulcers (n=10), gingival swelling (n=1) and angular cheilitis 
(n=1). Only aphthous ulcers and gingival swelling were found 
on the control group individuals, (n=1) each. (Figure 2)
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Halitosis Regurgitation Acid Taste Xerostomia Dysphagia Dysgeusia
 Control 21.2% 20.4% 16.8% 12.4% 10.6% 9.7%
 Study 13.8% 12.1% 8.6% 5.2% 1.7% 6.9%
FIGURE 1. Simplified Oral Hygiene Index, number of daily brushings, 
interdental cleaning and use of mouthwashes in the study and control 
groups.
Lesions of  the oral mucosa showed higher prevalence 
in the study group compared with the control group (8.8% 
versus 3.4%), even though this difference was not statistically 
significant (P=0.159).
The IBD group and the control group have also prevailed 
in several oral symptoms, such as halitosis, regurgitation, acid 
taste, xerostomia, dysphagia and dysgeusia. (Figure 3) The 
differences in the prevalence of oral symptoms in the study 
group when compared with the control group as presented in 
Figure 3, was statistically significant (P=0.011). Patients with 
IBD reported oral symptoms in 54.9% of cases compared 
with only 29.3% of the control group. Dysphagia (P=0.038) 
revealed to have a statistically significant association with 
IBD. Even when analyzed separately, none of  the other 
symptoms showed statistical significance for this association.
FIGURE 3. Distribution of oral symptoms in the study and control groups.
Activity of IBD
The oral mucosa lesions revealed a higher prevalence 
in the active phase of  the disease (35.3% versus 4.2%), 
(P<0.001). Aphthous ulcers proved to be the only type of 
affections with a statistically significant association to the 
active phase (P=0.001), with 35.3% of patients in the active 
stage diagnosed with this type of oral lesion versus 4.2% in 
remissive phase.
Patients in active phase reported oral symptoms in 70.6% 
of cases compared to only 52.1% of the patients in remis-
sion. This represented a statistically significant difference 
(P=0.001). Dysphagia (P=0.018), regurgitation (P=0.044) 
and acid taste (P=0.038) revealed to have a statistically sig-
nificant association with the active phase of IBD, even when 
analyzed separately.
Crohn’s disease vs ulcerative colitis
The oral mucosa lesions did not reveal a statistically 
significant difference in incidence between the patients 
diagnosed with CD and patients diagnosed with UC, 
(P=0.959). The oral symptoms did not show statistically 
significant difference between the groups with CD and UC 
either (P=0.697).
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When analyzed separately neither of  oral mucosa le-
sions or symptoms had a statistically significant relation 
with CD or UC.
Pharmacotherapy
Untreated patients at the time of  examination revealed 
no incidence of oral mucosa lesions (0%) and patients under 
corticosteroids treatment were the most affected by these 
lesions (22%). Nevertheless, considering all the different 
types of  medication used by the patients, the pharmacolog-
ical therapy of  IBD did not show a statistically significant 
relation with the presence of  lesions of  the oral mucosa 
(P=0.711).
Individuals that were not under any type of medication 
also revealed less incidence of  oral symptoms (38.5%). 
Patients taking salicylates were the least affected by these 
symptoms (50%), among medicated patients. On the op-
posite, 66.7% of  the patients under Immunossupressants 
and Corticosteroids reported oral symptoms. In spite of 
these results, there was no statistically significant relation 
between oral symptoms and the pharmacological therapy 
of IBD (P=0.052).
Smoking habits
Non-smokers were the most affected by lesions of  the 
oral mucosa with 9.57% (n=9), compared to 5.26% (n=1) 
of  the smokers group. This relation was not statistically 
significant (P=0.199).
When assessing the presence of oral symptoms between 
smoker patients and non-smoking patients no statistically 
significant relation was observed (P=0.595).
When analyzed separately neither of oral mucosa lesions 
or symptoms had a statistically significant relation with 
smoking habits.
Disease duration
The different types of  oral mucosa lesions showed a 
slight increasing tendency in incidence over the course of 
IBD, however, not in a statistically significant way (P=0.670).
Oral symptoms decreased over the course of  the dis-
ease, still this decrease was also not statistically significant 
(P=0.720).
When analyzed separately neither of oral mucosa lesions 
or symptoms had a statistically significant relation with the 
disease duration.
DISCUSSION
This was the first large study on oral health of Portuguese 
IBD patients, focusing a wide range of oral symptoms and 
mucosal lesions. In our study, patients within IBD group 
presented a higher prevalence of oral mucosal lesions when 
compared with the control group, supporting what was pre-
viously reported in the literature(2, 5, 12, 15, 25), although in our 
case without statistical significance. Patients with IBD often 
present more oral mucosal lesions than healthy controls, in 
accordance with the results of our study.
Few authors have studied the relation between IBD 
and its possible oral symptoms. The study by Katz and 
colleagues(15) was the first to establish this relation in a 
sample of  54 patients with IBD and 42 healthy subjects. As 
in our results, this study found that patients with IBD were 
more likely to experience oral symptoms when compared 
with a control group of  healthy individuals. More recently, 
other authors have confirmed the same findings for patients 
with UC(7).
In the active phase of  the disease, aphthous ulcers, 
proved to be the most common type of  lesion in the oral 
mucosa in our study (P=0.001), as already reported by 
some authors(14, 18). In those studies, no further association 
between any other type of  oral mucosa lesions and the ac-
tive phase of  IBD was established. Although these data are 
in agreement with our results, other authors(5, 12) in similar 
studies have not identified a correlation between activity 
of  IBD and any type of  oral mucosa lesions. Other lesions 
previously cited as possible manifestations of  IBD(4, 16) 
were unusual in our sample and, therefore, did not reach 
statistical significance in the present study.
There was a greater presence of symptoms in active phase 
of IBD, 70.6% of cases in the active phase compared to only 
52.1% of patients in remission, representing a statistically 
significant difference. A previous study, also pointed towards 
a higher incidence of  oral manifestations in active period 
of  the disease, however that study failed to demonstrate 
statistical significance(15).
In our sample 10.8% of CD patients presented oral mu-
cosa lesions against 11.4% of UC patients. This difference 
was not statistically significant. Other authors had already 
reported no significant differences in prevalence of lesions 
between both diseases(13). However, there have been reports 
in the literature considering that CD is more affected by oral 
lesions than UC(15, 17).
Although other studies(8, 9, 12, 19, 20, 24) associate pyostoma-
titis vegetans and orofacial granulomatosis with IBD, these 
data could not be confirmed in our population, since they 
showed no occurrence of  these lesions. The recent phar-
macotherapy of  IBD had significant impact on the natural 
history and clinical presentation of  patients. Eventually, 
the absence of  some classical oral lesions in our study, with 
a large number of  patients, may be result of  the modern 
treatment of  IBD.
Small differences can be found regarding oral symptoms 
between UC and CD, and those were not statistically signif-
icant. Similar conclusions were already disclosed in Katz(15) 
article, in which the author determined that even though both 
conditions showed a higher prevalence of  oral symptoms 
compared with the control group, no significant differences 
existed between them.
In which regards pharmacological treatment, our results 
revealed that untreated patients were the least affected by 
oral manifestations, and salicylates represent the therapy 
with fewer side effects. Although no statistically significant 
relation was established, the P-value 0.052 shows a statis-
tical trend towards a relation between some therapies and 
Laranjeira N, Fonseca J, Meira T, Freitas J, Valido S, Leitão J. Oral mucosa lesions and oral symptoms in Inflammatory Bowel Disease patients
v. 52 no. 2 - abr./jun. 2015  Arq Gastroenterol 109
higher incidence of  oral symptoms. Conversely, immuno-
suppressive therapy may be a surrogate marker of  a more 
severe IBD and oral manifestations may be more frequent 
in those patients.
In our sample, non-smokers have been the most affected 
by oral mucosa lesions with 9.57% against 5.26% of smokers, 
although this difference was not statistically significant. 57.89% 
of smoking patients reported oral symptoms against 54.26% 
of non-smokers, which is not a statistically significant relation.
When considering lesions of the oral mucosa, we observed 
a trend towards increase in incidence over the course of IBD 
duration. For oral symptoms, there was a downward trend in 
incidence over the course of the disease, even though none of 
these relations proved to be statistically significant.
CONCLUSION
A positive association between inflammatory bowel dis-
ease and oral mucosa lesions was established in this study, 
being IBD patients more affected, particularly in active 
phases of the disease. Aphthous ulcers were the most signif-
icant expression of this group of manifestations.
The oral symptoms were also associated with IBD, with 
dysphagia being the most reported symptom. Oral symp-
toms proved to be even more prevalent in active periods of 
the disease.
The time since disease onset and pharmacological reg-
imen may interfere with the incidence of  oral lesions and 
symptoms, although in this study the differences detected 
were not statistically significant. Oral lesions seem to increase 
over time, while oral symptoms seem to decrease, what may 
be attributable to the fact that the ongoing drug therapy 
diminished these oral manifestations.
The association between IBD and oral mucosa lesions 
and symptoms represents a clinical challenge that should 
encourage dentists to plan a careful follow-up of these pa-
tients, with the support of the gastroenterologist, in order 
to provide a better integrated treatment for these conditions.
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RESUMO - Contexto - A doença inflamatória intestinal é conhecida por suas manifestações extraintestinais, a cavidade oral não é exceção. Objetivos - O 
objetivo deste estudo foi o de avaliar a associação da doença inflamatória intestinal com lesões da mucosa oral e sintomatologia oral, e complementar-
mente, avaliar a sua possível relação com a higiene oral, tabagismo, terapêutica farmacológica, duração e atividade da doença. Métodos - Os pacientes 
foram selecionados no serviço de Gastroenterologia de um hospital de referência terciária Português (Hospital Garcia de Horta). Esta amostra foi 
composta por 113 pacientes previamente diagnosticados com colite ulcerosa ou doença de Crohn, juntamente com um grupo controle de 58 indivíduos 
saudáveis que acompanhavam os pacientes do grupo nas suas consultas de controle. Entrevistas clínicas e exames clínicos foram realizados para a 
coleta de dados. Resultados - Os pacientes do grupo de estudo foram mais afetados por sintomas orais (P=0,011), e houve também uma tendência 
para uma maior incidência de lesões da mucosa oral, embora a significância estatística não tenha sido alcançada (8,8% versus 3,4% no grupo de 
controle; P=0,159). Pacientes em fase ativa foram os mais afetados. Não foram detetadas diferenças entre a doença de Crohn e a colite ulcerosa, ou 
relativas a hábitos tabágicos. O tratamento com corticosteroides e imunossupressores pareceu aumentar a incidência de sintomas orais (P=0,052). 
Os dados são ainda compatíveis com aumento das lesões da mucosa oral e diminuição dos sintomas ao longo do curso da doença, no entanto, sem 
significância estatística. Conclusão - As lesões de mucosa oral e sintomas orais foram associados positivamente com a doença inflamatória intestinal, 
principalmente durante os períodos de atividade da doença e possivelmente, associado a terapêutica com corticosteroides e imunossupressores. 
DESCRITORES - Doenças inflamatórias intestinais. Estomatite aftosa. Mucosa bucal.
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